SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-103717
Filing Date
2022-04-13
Accepted
2022-04-13 09:00:56
Documents
12
Period of Report
2022-04-11
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d352921d8k.htm   iXBRL 8-K 24503
  Complete submission text file 0001193125-22-103717.txt   149670

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fusn-20220411.xsd EX-101.SCH 2860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fusn-20220411_lab.xml EX-101.LAB 18690
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fusn-20220411_pre.xml EX-101.PRE 11695
6 EXTRACTED XBRL INSTANCE DOCUMENT d352921d8k_htm.xml XML 3517
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39344 | Film No.: 22823772
SIC: 2836 Biological Products, (No Diagnostic Substances)